Insomnia in a Bundle Is Still a Drug Claim

What Copy Pulled the Intelligent Remedies Letter in January 2026?

FDA's warning letter to Intelligent Remedies, Inc. (CMS #681941), issued January 23, 2026 and posted that May, quotes the company's own product page: 'Anxiety Support is specially formulated to combat anxiety and insomnia. It has other positive effects including ... lowering your blood pressure.'

The label carried a second line, 'Control Anxiety,' and the blood pressure promise sitting in that same sentence is itself already a drug claim on its own, the subject of 'Promotes Low Blood Pressure' Is Already a Drug Claim. We can't isolate insomnia as the sole trigger here; FDA's letter treats the passage as one block of evidence, not three separable promises.

The same letter covers nine products, each pinned to a different disease.

Why Did a Bare Numbered Condition List Count as Intended Use in the Hekma Case?

A bare list counted because FDA's intended-use test looks at what a list communicates, not whether a verb attaches to it. In its June 2, 2023 letter to Hekma Center, LLC (CMS #637652), classified Unapproved New Drugs/Misbranded, FDA cited a numbered condition list on the product page in which '15. Insomnia' sat between '14. As a tranquilizer to reduce stress' and '16. Impotence.'

No sentence promised relief and no mechanism was described. The list alone — insomnia sitting next to hypertension, dementia, Alzheimer's and multiple sclerosis — was sufficient, because FDA's intended-use doctrine treats labeling context and the circumstances of distribution as evidence, not just an express promise of a cure.

A condition name is a claim by itself.

How Does Condition Bundling Work Commercially, and Why Does It Keep Happening?

Condition bundling happens because the lawful half of the copy is what a relaxation supplement can say honestly, and the unlawful half is what converts better, so advertisers fuse the two into one product rather than choosing. FDA's enforcement record documents the pattern in three separate letters.

The single-mechanism narrative these ads run on doesn't match what the National Institutes of Health says about who actually has insomnia and why. MedlinePlus, the National Library of Medicine's consumer site, describes insomnia as common, more frequent in women than men, and elevated by stress, depression, shift work, long-distance travel and an inactive lifestyle, and it states plainly that most chronic cases are secondary — a symptom of another condition rather than a standalone problem one ingredient resolves. That secondary-cause structure is also part of why demand for sleep offers itself moves with the calendar, a pattern we cover separately in Sleep Offer Seasonality: Daylight Saving and Winter Demand. Buyers often assume that splitting the anxiety SKU from the sleep SKU under different brand names creates separation between the two risk profiles; the enforcement record doesn't support that assumption, since FDA reads an entire web presence as one labeling document regardless of how many product names sit on it.

• Intelligent Remedies (January 2026): an anxiety-branded product combines anxiety, insomnia and a blood pressure promise inside one sentence.
• AnuMed International (August 2024): a 'Hormones / Mood / Sleep' label paired with a blog page tying vitamin D deficiency to sleeping disorders.
• Hekma Center (June 2023): insomnia embedded in a numbered condition list alongside hypertension, dementia and Alzheimer's, with no verb attached to any of them.

Does the Lawful Relaxation Half of the Copy Protect the Unlawful Half?

No — one disease word inside otherwise lawful relaxation copy sets the classification for the surrounding document, not the other way around.

FDA's own final rule preamble draws the line by duration, not vocabulary, warning that unless the surrounding copy establishes an occasional-sleeplessness frame, 'unless the context makes clear that the product is only for occasional sleeplessness, they imply treatment of insomnia, a disease.'

We checked whether the standard structure/function disclaimer changes that outcome, and it doesn't: 21 CFR 101.93(f) states that labeling bearing a disease claim makes the product a drug unless the claim is an authorized health claim the product qualifies for. The disclaimer only accompanies a lawful claim; it doesn't convert an unlawful one, no matter how prominently it's printed underneath.

How Far Across a Domain Does Labeling Reach — Product Page, Blog, Ingredient Page?

Labeling reaches the whole domain: product page, blog post, ingredient page, and the social accounts and marketplace listings linked from it.

FDA's September 2021 letter to Live Good Inc., over its Berry Gen Sugar Control product, built its intended-use finding from four separate channels at once — the company website, its Facebook and Instagram pages, and its Amazon storefront. The letter closes by noting that the FTC had reviewed the same web presence the month before, one set of pages read as labeling by two different agencies.

An ingredient-education page written in pharmacology register carries the same weight as the product page that sells the SKU, which is the argument we make in full in When the Ingredient Is the Drug Claim.

What Happens to Google Ads Eligibility Once a Letter Exists?

The account doesn't get a second chance — a warning letter is itself a permanent disqualifier under Google's Unapproved substances policy, independent of whatever copy the advertiser fixes afterward.

Google's own policy text draws no distinction between an active violation and a resolved one; it bans 'Products that have been subject to any government or regulatory action or warning,' full stop.

The same policy separately bars claims that a product works as well as a prescription drug, which catches sleep positioning built against a hypnotic. A line like 'without the grogginess of a sleeping pill' reads as ordinary conversion copy, but it satisfies Google's rule and FDA's substitute-for-a-therapy criterion at 21 CFR 101.93(g)(2)(vi) at the same time.

Which Sleep-Adjacent Conditions Carry Their Own Separate Exposure?

Four adjacent conditions carry exposure of their own, each governed by a different rule than plain insomnia copy would trigger alone.

Snoring carries an affirmative disclosure duty that footer text doesn't satisfy. FTC's Health Products Compliance Guidance walks through a nasal-strip snoring ad and states that 'a disclosure immediately next to the snoring claim in the same font size ... is much more likely to be effective' than one buried below the fold.

How Should a Buyer Pressure-Test a Merchant's Full Site Before Running Traffic?

Read the whole site the way FDA does: as one labeling document, not as separate pages carrying separate risk.

A full-text search of FDA's own warning-letter database for 'insomnia' turns up 72 letters as of early August 2026 — a large enough count that treating sleep claims as a low-probability risk misreads the record.

One piece of this checklist we couldn't verify directly: Meta's live Ad Standards pages covering personal-health and before/after imagery returned an empty, script-rendered response rather than policy text during our research. We're reporting the rule from its previously documented wording rather than a fresh read, and confirming it means loading transparency.meta.com's ad-standards pages in a browser that executes JavaScript and reading the current text before a sleep-and-anxiety campaign goes live.

• Every product page and every blog post the domain has published, since FDA's letters treat both as labeling.
• Ingredient or 'about the science' pages written in pharmacology register — GABA agonist, cortisol-lowering, dopamine-raising — vocabulary FDA has cited as drug evidence in adjacent verticals.
• Linked Facebook, Instagram and Amazon storefronts, which FDA reviewed alongside the main site in its Live Good Inc. letter.
• Where the required disclaimer sits relative to any claim it's supposed to qualify — adjacent and boxed, not a footer link.
• Any numbered condition list, quiz or 'is this you?' funnel that names a disease without a verb attached to it.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, Search the Warning-Letter Index Before You Take an Offer, Hearing Offers Blame an Industry, Not a Biology, Hot Flashes Are Legal. Amberen Still Got Sued., Nerve VSL Claims: What Needs Its Own Proof, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.